Lineage Cell Therapeutics (LCTX) Non-Current Debt (2015 - 2017)

Lineage Cell Therapeutics' Non-Current Debt history runs 3 years deep, the most recent figure standing at $18000.0 for Q4 2017.

• On a quarterly basis, Non-Current Debt fell 85.0% year-over-year to $18000.0 in Q4 2017; TTM through Dec 2017 was $18000.0, a 85.0% decrease from a year earlier, with the FY2017 full-year figure at $18000.0, down 85.0% from the prior year.
• Non-Current Debt declined to $18000.0 in Q4 2017 per LCTX's latest filing, from $44000.0 in the prior quarter.
• Across five years, Non-Current Debt topped out at $268000.0 in Q3 2015 and bottomed at $18000.0 in Q4 2017.
• The 3-year median for Non-Current Debt is $146500.0 (2016), against an average of $142600.0.
• Across the five-year window, Non-Current Debt slumped 35.45% in 2016 and tumbled 85.0% in 2017, its largest moves.
• Year by year, Non-Current Debt stood at $220000.0 in 2015, then plunged by 45.45% to $120000.0 in 2016, then tumbled by 85.0% to $18000.0 in 2017.
• Per Business Quant, the three latest LCTX Non-Current Debt figures stand at $18000.0 (Q4 2017), $44000.0 (Q3 2017), and $95000.0 (Q2 2017).